ReviewNature reviews. Clinical oncology2009
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
Review in Nature reviews. Clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- CDCA3 Predicts Poor Prognosis and Affects CD8Journal of oncology · 2022Article
- Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma.Translational oncology · 2020Article
- Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.Molecular therapy oncolytics · 2016Article
- Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy.International journal of cancer · 2014Article
- Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.World journal of urology · 2014Review
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.Nature reviews. Clinical oncology · 2014Review
- Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.The Journal of biological chemistry · 2013Article
- Novel immunotherapies in GU malignancies.Current oncology reports · 2013Review
- Article
- Tivozanib in the treatment of renal cell carcinoma.Biologics : targets & therapy · 2013Article
- Targeting the tumor microenvironment: focus on angiogenesis.Journal of oncology · 2012Article
- Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway.The Journal of biological chemistry · 2011Article
- A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2011Article
- Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden.Neoplasia (New York, N.Y.) · 2010Article
- Signaling pathways in renal cell carcinoma.Cancer biology & therapy · 2010Review
- Update on vaccine development for renal cell cancer.Open access journal of urology · 2010Review
- Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Expert opinion on biological therapy · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FDA approval of the multitargeted, antiangiogenic tyrosine kinase inhibitors (TKIs) sunitinib and sorafenib, and the serine and threonine mammalian target of rapamycin inhibitor, temsirolimus, has revolutionized the management of metastatic clear-cell renal-cell carcinoma (CC-RCC). The inability of these targeted therapies to provide durable complete responses, however, is a serious limiting factor to their clinical usefulness. Although immunotherapeutic approaches in advanced disease are increasingly regarded as a historical treatment paradigm, we propose that a fundamental understanding of immunobiology in CC-RCC can improve the selection of patients for high-dose intravenous interleukin 2 and facilitate the development of novel immunotherapeutic strategies. In our opinion, immunotherapeutic strategies have an important place in the management of advanced CC-RCC in the era of biological targeted therapy.
Indexed as
Identifiers
19546865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.